Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15282483 | 0.95 | LMNA (0.50) | LMNABBOX1 | |
| SCHEMBL16804318 | 0.95 | LMNA (0.57) | LMNABBOX1APP | |
| SCHEMBL16724858 | 0.85 | LMNA (0.38) | LMNABBOX1APP | |
| SCHEMBL4309125 | 0.83 | APP (0.41) | LMNAAPP | |
| SCHEMBL1970826 | 0.83 | BBOX1 (0.55) | LMNABBOX1 | |
| SCHEMBL15292330 | 0.82 | LMNA (0.36) | LMNABBOX1APP | |
| SCHEMBL2616658 | 0.81 | APP (0.39) | LMNAAPP | |
| SCHEMBL918271 | 0.81 | BBOX1 (0.46) | LMNABBOX1APP | |
| SCHEMBL30054204 | 0.80 | BBOX1 (0.37) | LMNABBOX1APP | |
| Hydrochloric Acid SCHEMBL1971576 | 0.79 | LMNA (0.73) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379118-B1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GEN ELECTRIC (US) | 2017-10-18 | — | — | EP | claimed |
| US-9196405-B2 | Stable iron oxide nanoparticles and method of production | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2015-11-24 | — | — | US | claimed |
| US-20140147387-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2014-05-29 | — | — | US | claimed |
| US-8728529-B2 | Nanoparticle contrast agents for diagnostic imaging | GENERAL ELECTRIC COMPANY (US) | 2014-05-20 | — | — | US | claimed |
| US-8574549-B2 | Nanoparticle contrast agents for diagnostic imaging | GENERAL ELECTRIC COMPANY (US) | 2013-11-05 | — | — | US | claimed |
| US-20130256583-A1 | Stable Iron Oxide Nanoparticles and Method of Production | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2013-10-03 | — | — | US | claimed |
| US-20100166664-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | claimed |
| US-20100166665-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | claimed |
| US-20230341411-A1 | METHOD AND KIT OF MEASURING CONCENTRATION OF ANALYTE | NATIONAL CHUNG CHENG UNIVERSITY (TW) | 2023-10-26 | — | — | US | disclosed |
| US-20200277660-A1 | SYSTEM AND METHOD FOR DETECTION OF NUCLEIC ACIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-09-03 | — | — | US | disclosed |
| US-10626448-B2 | System and method for detection of nucleic acids | ALVEO TECHNOLOGIES, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10627358-B2 | Method for detection of analytes | ALVEO TECHNOLOGIES, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10352899-B2 | System and method for detection of silver | ALVEO Technologies Inc. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190144926-A1 | SYSTEM AND METHOD FOR DETECTION OF NUCLEIC ACIDS | ALVEO Technologies Inc. | 2019-05-16 | — | — | US | disclosed |
| US-20100166666-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100166664-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100166665-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20090202816-A1 | STABILIZED SILICA COLLOID | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090202816-A1 | STABILIZED SILICA COLLOID | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2007146680-A1 | STABILIZED SILICA COLLOID | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION , INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140147387-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | CD47, CD63, MACO1 | LMNA 1475/4885BBOX1 2817/4885APP 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.